Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. (Q42972731)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2010

Language	Label	Description	Also known as
English	Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS.	scientific article published on September 2010

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. (English)

1 reference

Europe PubMed Central

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

Alessandro D Genazzani

object named as

Alessandro D Genazzani

1

0 references

author name string

Elisa Chierchia

2

1 reference

Europe PubMed Central

12 November 2017

Erika Rattighieri

3

1 reference

Europe PubMed Central

12 November 2017

Susanna Santagni

4

1 reference

Europe PubMed Central

12 November 2017

Elena Casarosa

5

1 reference

Europe PubMed Central

12 November 2017

Michele Luisi

6

1 reference

Europe PubMed Central

12 November 2017

Andrea R Genazzani

7

1 reference

Europe PubMed Central

12 November 2017

publication date

1 September 2010

1 reference

Europe PubMed Central

12 November 2017

Gynecological Endocrinology

1 reference

Europe PubMed Central

12 November 2017

26

1 reference

Europe PubMed Central

12 November 2017

9

1 reference

Europe PubMed Central

12 November 2017

684-689

1 reference

Europe PubMed Central

12 November 2017

Neurosteroids Biosynthesis and function.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

In vivo secretion of 3 alpha-hydroxy-5 alpha-pregnan-20-one, a potent anaesthetic steroid, by the adrenal gland of the rat.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Neurosteroids: a new brain function?

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Neurosteroid metabolism. 7 alpha-Hydroxylation of dehydroepiandrosterone and pregnenolone by rat brain microsomes

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Time-dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Allopregnanolone concentration in hippocampus of prepubertal rats and female rats throughout estrous cycle.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Non-genomic and genomic effects of steroids on neural activity

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Progesterone as a neurosteroid: actions within the nervous system.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Changes in adrenocortical function with aging and therapeutic implications

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin, or gonadal steroid plasma levels in amenorrheic women.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Circulating levels of neuroactive steroids in patients with binge eating disorder: A comparison with nonobese healthy controls and non‐binge eating obese subjects

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Allopregnanolone concentrations and premenstrual syndrome.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Disadaptive disorders in women: allopregnanolone, a sensitive steroid.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36).

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Increased risk of depressive disorders in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Progesterone and progestins: effects on brain, allopregnanolone and beta-endorphin

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2010.500818

21 January 2018

Identifiers

10.3109/09513590.2010.500818

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42972731&oldid=1590135986"